



Application of New Molecular Probes in the Diagnosis and Treatment of Malignant Tumors

Guest Editors:

Dr. Hui Lu

Department of Orthopedics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

Dr. Dengfeng Cheng

Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China

Deadline for manuscript submissions:

closed (31 March 2023)

Message from the Guest Editors

Molecular probes are divided into different types of probes, such as nuclear medicine, optical, magnetic, acoustic, photoacoustic, etc., which are the prerequisite and core technologies for realizing molecular imaging. In recent years, this technology has developed rapidly, and some molecular probes have been clinically transformed. The multimodal molecular imaging of tumors can detect tumors at an early stage, support clinical staging, guide the decision-making of clinical drugs and surgical treatment, and predict and evaluate the effect of cancer treatment. The growing research of some molecular probes with the integration of diagnosis and treatment not only enables the diagnosis and staging the tumor, but also provides personalized treatment for the specific target of the tumor, providing a new strategy for tumor diagnosis and treatment.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)